Preventive Health Services

5

Review clinical trials related to Preventive Health Services. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Longevity Metrics AI/ML Development Study

This study builds AI models that score diagnostic screening tests, and that predict screening results, clinical judgment, and life expectancy. Longevity Metrics collects a battery of clinical tests on each participant, in whole or in part, and follows every participant for life. The sit-to-rise test and the timed walk are scored by hand today, from a person's count. A model scores the same test from video instead. It also measures what no one can count by eye - speed, asymmetry, steadiness - so one capture yields both the original score and additional measurements, intended to enrich the model and strengthen what it predicts. Every test in a participant's record measures the same body, so the tests are correlated: a test that was performed carries information about one that was not. A model trained across the library learns those relationships and estimates a missing result from the results that are present. Each estimate is checked against records where that part was actually measured, and over decades against death and disease through linkage to the 100-Year Human Aging Study (NCT07563777). The hypothesis is that the full battery can eventually be predicted across modalities with high accuracy using a few short video clips, replacing most in-person screening. That would let preventive screening reach people and places a physical laboratory cannot. How far the input can be reduced is the question this study exists to answer. Every model is a physician-reviewed clinical decision aid until it is cleared by the FDA.

Participants needed: 1,000,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Longevity Metrics, Inc.Updated: Sep 9, 2026Locations: 1
Eligibility criteria

Age >= 18 [+1]

Age < 18 years

Status: Recruiting

Health Ahead Comparative Effectiveness Study

The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each change is isolated as a single variable against current practice, and every comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, so results accumulate on a consistent yardstick across the life of the platform. The first comparison evaluates AI-assisted versus human-only interpretation ("reads") of screening data. Subsequent pre-planned comparisons, added by protocol amendment, evaluate static versus interactive personalized report delivery; mobile community versus fixed laboratory screening; and a hybrid medical-droid-plus-human delivery model versus human-only screening.

Participants needed: 1,000,000
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: William Brandenburg, MDUpdated: Sep 8, 2026Locations: 1
Eligibility criteria

Age 18 years or older [+2]

Status: Recruiting

Improving LDL-C Levels Through Temporal Self-regulation Theory-based, Personality-tailored Health Messages

The study is meant to run parallel to the larger study, RESET. The goal of this study is to to evaluate the effectiveness of a once-off general and personality-tailored text message on GP consultation among RESET participants identified to have high LDL-C. The main question it aims to answer is: Will participants exposed to personality tailored advice have a higher adherence to GP consultation compared to the participants in the control group? Researchers will compare a personalized message to a general message (with no personalization according to patients personality type) and control group to see if the messages increase adherence. Participants are required to complete two questionnaires: one before and one after they receive their RESET results.

Participants needed: 3,000
Trial details
Age: 21-65Biological sex: AllType: InterventionalSponsor: National University Health System, SingaporeUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

New participants of RESET who have given consent to be contacted for future stud... [+1]

are not able to read, write or communicate in English

Status: Recruiting

The VIA Family 2.0 - a Family Based Intervention for Families with Parental Mental Illness

VIA Family 2.0 - a Family Based Intervention for families with parental mental illness Background: Children born to parents with mental illness have consistently been shown to have increased risks for a range of negative life outcomes including increased frequencies of mental disorders, somatic disorders, poorer cognitive functioning, social, emotional and behavioral problems and lower quality of life. Further these children are often overlooked by both society and mental health services, although they represent a potential for prevention and early intervention. A collaboration between researchers and clinicians from two regions, the Capital Region and the North Region Denmark has been established as the Research Center for Family Based Interventions. The research center is an umbrella for a series of research activities, all focusing on children and adolescents in families with parental mental illness. Method: A large randomized, controlled trial (RCT) for families with parental mental illness will be conducted in order to evaluate the effect of a two-year multidisciplinary, holistic team intervention (the VIA Family 2.0 team intervention) against treatment as usual (TAU). Inclusion criteria will be biological children 0-17 of parents with any mental disorder treated in the secondary sector at any time of their life and receiving treatment in primary or secondary sector within the previous three years. A total of 870 children or approx. 600 families will be included from two sites. Primary outcomes will be changes in child well being, parental stress, family functioning and quality of the home environment, . Time plan: The RCT will start including families from March 1st, 2024 to Dec 2025 (or later if needed). All families will be assessed at baseline and at end of treatment, i.e. after 24 months and after 36 months. Baseline data will inform the intervention team about each family's needs, problems, and motivation. TAU will be similar in the two regions, which means three family meetings and option for children to participate in peer groups. Challenges: final funding is being applied for. Recruitment of families can be challenging but we have decades of experience in conducting research in the field. Since both the target group, their potential problems and the intervention is complex, primary outcome is difficult to determine.

Participants needed: 1,452
Trial details
Age: 0-17Biological sex: AllType: InterventionalSponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalUpdated: Oct 26, 2024Locations: 1
Eligibility criteria

At least one of the parents must be living in Capital Region or in Region North,... [+3]

Not fulfilling inclusion criteria [+5]

Status: Recruiting

PCOM2 - The Physician Communication Intervention, Version 2.0

Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, was found to be effective for increasing adolescent HPV vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. To address this, investigators propose to develop and test a virtual version of PCOM, use mixed methods to assess contextual factors affecting its use compared to the original PCOM intervention, and develop an optimized version of PCOM for broad dissemination to increase adolescent HPV vaccination nationally.

Participants needed: 120
Trial details
Age: 9-17Biological sex: AllType: InterventionalSponsor: University of Colorado, DenverUpdated: Aug 26, 2024Locations: 2
Eligibility criteria

Parents: Have an adolescent between the ages of 9-17 years old and receiving ado... [+1]

Parents: Does not have an adolescent between the ages of 9-17 years old and is n... [+1]